专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120021036A1 COMPOSITE NANOSTRUCTURES AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译：复合纳米结构及其制备与使用方法
公开(公告)号：US20120021036A1
公开(公告)日：2012-01-26
申请号：US13143825
申请日：2010-01-14
申请人： Bharat Majeti , Eric Murphy , Wolfgang Wrasidlo , David Cheresh
发明人： Bharat Majeti , Eric Murphy , Wolfgang Wrasidlo , David Cheresh
IPC分类号： A61K9/14 , A61K31/7068 , A61K38/22 , A61K31/196 , A61K31/675 , A61K31/519 , A61K31/52 , A61K31/513 , A61K31/704 , A61K38/14 , A61K31/135 , A61K31/167 , A61K31/573 , A61K38/46 , A61K33/24 , A61K31/7048 , A61K38/19 , A61K31/337 , A61K38/20 , A61K31/437 , A61P35/00 , A61K9/00 , B82Y5/00
CPC分类号： A61K31/337 , A61K9/0024 , A61K9/1273 , A61K38/00 , A61K45/06 , A61K47/62 , A61K47/643 , A61K47/6903 , A61K47/6911 , A61K2300/00
摘要： The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartments which in unison function as a composite nanostructure. In one embodiment, the nanoparticles of the invention comprise a combination of polymer core/lipid bilayer interface which incorporate covalently attached lipid-vascular targeting ligands. These composite nanoparticles can deliver highly effective and selective payloads for diagnostic, prophylactic or therapeutic applications.
摘要翻译：本发明提供用作离体或体内组合物（例如药物或治疗性，诊断或成像试剂）递送载体的纳米结构或制造产品。在一个方面，本发明提供纳米颗粒，其包含几个隔室，其一致地用作复合纳米结构。在一个实施方案中，本发明的纳米颗粒包含掺入共价连接的脂质 - 血管靶向配体的聚合物核心/脂质双层界面的组合。这些复合纳米颗粒可以为诊断，预防或治疗应用提供高效和有选择的有效载荷。

2. 发明申请

US20130266636A1 METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION 审中-公开
标题翻译：阻断细胞增殖和治疗细胞生长抑制的疾病和病症的方法
公开(公告)号：US20130266636A1
公开(公告)日：2013-10-10
申请号：US13816218
申请日：2011-08-12
申请人： David Cheresh , Eric Murphy , Ainhoa Mielgo
发明人： David Cheresh , Eric Murphy , Ainhoa Mielgo
IPC分类号： A61K31/506
CPC分类号： A61K31/506 , A61K31/4164 , A61K31/4196
摘要： In alternative embodiments, the invention provides methods for regulating or modulating RAF kinases. In alternative embodiments, the invention provides methods for ameliorating, preventing and/or treating diseases, infections and/or conditions having unwanted, pathological or aberrant cell proliferation, or that are responsive to inhibition or arrest of cell growth, by administration of an allosteric RAF inhibitor and/or any agent which prevents localization of RAF to mitotic spindles or mid-bodies.
摘要翻译：在替代实施方案中，本发明提供了调节或调节RAF激酶的方法。在替代实施方案中，本发明提供了通过施用变构的RAF来改善，预防和/或治疗具有不想要的，病理学或异常细胞增殖或对抑制或阻止细胞生长有反应的疾病，感染和/或病症的方法抑制剂和/或阻止RAF定位于有丝分裂心轴或中间体的任何药剂。

3. 发明申请

US20070036751A1 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies 有权
标题翻译：使用抗血管生成和免疫疗法的组合治疗肿瘤和转移的方法
公开(公告)号：US20070036751A1
公开(公告)日：2007-02-15
申请号：US11527029
申请日：2006-09-26
申请人： Holger Lode , Ralph Reisfeld , David Cheresh , Stephen Gillies
发明人： Holger Lode , Ralph Reisfeld , David Cheresh , Stephen Gillies
IPC分类号： A61K39/395 , A61K38/19 , A61K38/20 , A61K38/21
CPC分类号： C07K7/64 , A61K38/00 , A61K38/19 , A61K38/2013 , A61K39/395 , A61K45/06 , A61K47/6813 , A61K2300/00
摘要： The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
摘要翻译：本发明提供了治疗哺乳动物肿瘤和肿瘤转移的方法，包括向需要治疗的哺乳动物施用治疗量足以抑制血管生成的拮抗剂与治疗量的抗肿瘤免疫治疗剂（例如抗肿瘤抗原抗体/细胞因子融合蛋白，其具有足以引发细胞因子特异性生物反应的细胞因子和重组免疫球蛋白多肽链。

4. 发明申请

US20050002936A1 Methods and compositions useful for inhibition of angiogenesis 失效
标题翻译：用于抑制血管生成的方法和组合物
公开(公告)号：US20050002936A1
公开(公告)日：2005-01-06
申请号：US10892789
申请日：2004-07-15
申请人： Peter Brooks , David Cheresh
发明人： Peter Brooks , David Cheresh
IPC分类号： A61K39/00 , C12N15/02 , A61K38/00 , A61K39/395 , A61K45/00 , A61P27/02 , A61P29/00 , A61P35/00 , C07K14/705 , C07K14/78 , C07K16/28 , C07K16/30 , C12P21/08
CPC分类号： C07K14/78 , A61K38/00 , A61K2039/505 , C07K14/70557 , C07K16/2848 , C07K16/30
摘要： The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.
摘要翻译：本发明描述了使用玻连蛋白α-角蛋白3拮抗剂抑制组织中血管生成的方法，特别是用于抑制发炎组织和肿瘤组织中的血管生成以及使用含有阿尔巴博3拮抗剂的治疗组合物的转移。

5. 发明申请

US20060270710A1 Methods for inhibition of angiogenesis 审中-公开
标题翻译：抑制血管发生的方法
公开(公告)号：US20060270710A1
公开(公告)日：2006-11-30
申请号：US11498620
申请日：2006-08-03
申请人： Peter Brooks , David Cheresh
发明人： Peter Brooks , David Cheresh
IPC分类号： A61K31/4439 , A61K31/433 , A61K31/4178 , A61K31/198
CPC分类号： A61K31/5415 , A61K31/00 , A61K31/198 , A61K31/352 , A61K31/4168 , A61K31/4178 , A61K31/4184 , A61K31/433 , A61K31/4439 , A61K31/47 , A61K31/498 , A61K31/538 , A61K38/04 , A61K38/16 , A61K38/4886 , C07C279/14 , C07C311/06 , C07C311/10 , C07C2602/42 , C07D263/38 , C07K14/75 , C07K16/2839 , C07K16/2848 , C12N9/6491
摘要： The present invention describes methods for inhibition angiogenesis in tissues using organic peptidomimetic αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists. The antagonists are organic compounds having a basic group and an acidic group spaced from one another by a distance in the range of about 10 Angstroms to about 100 Angstroms, as described in detail herein.
摘要翻译：本发明描述了使用有机拟肽α3β3拮抗剂抑制组织中的血管生成的方法，特别是用于抑制发炎组织和肿瘤组织中的血管生成以及使用治疗组合物含有α3β3拮抗剂。拮抗剂是具有碱性基团和酸性基团的有机化合物，其间距离在约10埃至约100埃的范围内，如本文详细描述的。

6. 发明申请

US20060165703A1 Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis 审中-公开
标题翻译：用于抑制αvβ5介导的血管生成的方法和组合物
公开(公告)号：US20060165703A1
公开(公告)日：2006-07-27
申请号：US11290896
申请日：2005-11-29
申请人： Peter Brooks , David Cheresh , Martin Friedlander
发明人： Peter Brooks , David Cheresh , Martin Friedlander
IPC分类号： A61K39/395 , A61K39/00 , C07K14/82 , C07K16/30
CPC分类号： A61K38/57 , A61K2039/505 , C07K16/2839 , C07K16/2848 , C07K2317/76
摘要： The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin αvβ5 antagonists. The αvβ5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of αvβ5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing αvβ5 antagonists.
摘要翻译：本发明描述了使用玻连蛋白α5β5拮抗剂抑制组织中血管生成的方法。 α-β5介导的血管发生与包括血管内皮生长因子，转化生长因子-α和表皮生长因子在内的细胞因子的暴露相关。使用含有αV的治疗组合物，在血管内皮细胞新生血管疾病，肿瘤生长和炎性病症中，对α5β5介导的血管生成的抑制是特别优选的 5β拮抗剂。

7. 发明申请

US20100209488A1 PROTEIN KINASE MODULATING COMPOUNDS AND METHODS FOR MAKING AND USING THEM 审中-公开
标题翻译：蛋白激酶调节化合物及其制备和使用方法
公开(公告)号：US20100209488A1
公开(公告)日：2010-08-19
申请号：US12602759
申请日：2008-07-15
申请人： Wolfgang Wrasidlo , Eric Murphy , David Cheresh
发明人： Wolfgang Wrasidlo , Eric Murphy , David Cheresh
IPC分类号： A61K31/5377 , C07D413/14 , A61K9/127 , A61K9/14 , C12N9/99 , A61P35/00 , A61P9/00 , A61P25/00 , A61P3/10 , A61P29/00 , A61P9/12 , A61P35/02 , A61P35/04
CPC分类号： C07D403/12
摘要： The invention provides compositions, e.g., small molecules, that disrupt the activity of protein kinases, including constitutively activated protein kinases, such as kinases constitutively activated through mutations, and kinases in their native inactivated state, and methods for making and using them. In one aspect, compositions of the invention bind a protein kinase in its inactive conformation involving the conserved asparagine-phenylalanine-glycine residue motif, or “Asp-Phe-Gly” or “DFG” motif, of the activation loop in the allosteric binding site. The small molecule protein kinase inhibitors of the invention comprise or are derivatives or analogs of oxadiazoles, thiadiazoles, oxazoles, thiazoles, arylamides, quinolones, pyrazoles, pyrazolones, imides, pyrolles, imidazoles and/or triazoles.
摘要翻译：本发明提供了破坏蛋白激酶（包括组成型激活的蛋白激酶）的组合物，例如小分子，例如通过突变组成型激活的激酶，以及其天然失活状态的激酶，以及制备和使用它们的方法。在一个方面，本发明的组合物结合涉及保守的天冬酰胺 - 苯丙氨酸 - 甘氨酸残基基序的无活性构象的蛋白激酶或者在变构结合位点中的活化环的“Asp-Phe-Gly”或“DFG”基序。本发明的小分子蛋白激酶抑制剂包含恶二唑，噻二唑，恶唑，噻唑，芳基酰胺，喹诺酮，吡唑，吡唑啉酮，酰亚胺，吡咯烷，咪唑和/或三唑的衍生物或类似物。

8. 发明申请

US20060211769A1 Methods for inhibiting angiogenesis and tumor growth 有权
标题翻译：抑制血管生成和肿瘤生长的方法
公开(公告)号：US20060211769A1
公开(公告)日：2006-09-21
申请号：US11439918
申请日：2006-05-24
申请人： Dale Boger , David Cheresh
发明人： Dale Boger , David Cheresh
IPC分类号： A61K31/195
CPC分类号： A61K31/195 , A61K31/165 , A61K31/27
摘要： Angiogenesis, tumor growth, and metalloproteinase 2 (MMP2) interaction with integrin-αvβ3 are inhibited by an inhibitor compound of formula: wherein G1 and G2 are each independently —NH—C(O)—O—(CH2)v—(C6H4)—X3; Y1 and Y2 are each independently —OH or C1-C4 alkoxy; X1 and X2 are each independently halo or C1-C4 alkoxy; X3 is fluoro, nitro, C1-C4 alkyl, C1-C4 alkoxy, or C1-C4 perfluoroalkyl; Z is —C≡C—, —C6H4—, cis —CH═CH—, trans —CH═CH—, cis —CH2—CH═CH—CH2—, trans —CH2—CH═CH—CH2—, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each 1; t is an integer having a value of 0 or 1; p and r are each 2, and v is 1; with the proviso that when A is H, t is 0, and when A is a covalent bond, t is 1.
摘要翻译：血管生成，肿瘤生长和金属蛋白酶2（MMP2）与整联蛋白α3β3的相互作用被下式的抑制剂化合物抑制：其中G 1，（O）-O-（CH 2）2 - （C 1 -C 6） 6 H 4）-X 3; Y 1和Y 2各自独立地为-OH或C 1 -C 4烷氧基; X 1和X 2各自独立地为卤素或C 1 -C 4烷氧基; X 3是氟，硝基，C 1 -C 4烷基，C 1 -C 4 烷氧基或C 1 -C 4全氟烷基; Z是-C≡C - ， - C 6 H 4 - ，顺式-CH-CH-，反式-CH-CH-，顺式-CH 2 -CH-CH-CH 2 - ，反式-CH 2 -CH-CH-CH 2 - ，1,4 顺式-1,3-环己基，反式-1,3-环己基，顺式-1,4-环己基或反式-1,4-环己基; A是H或共价键; m和n分别为1; t是值为0或1的整数; p和r各自为2，v为1; 条件是当A为H时，t为0，当A为共价键时，t为1。

9. 发明申请

US20060040853A1 Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras 审中-公开
标题翻译：使用蛋白激酶Raf和Ras调节血管发生的方法和组合物
公开(公告)号：US20060040853A1
公开(公告)日：2006-02-23
申请号：US11219264
申请日：2005-09-02
申请人： John Hood , Brian Eliceiri , David Cheresh
发明人： John Hood , Brian Eliceiri , David Cheresh
IPC分类号： A61K38/48 , A61K9/127
CPC分类号： A61K38/45 , A61K48/00
摘要： The present invention describes methods for modulating angiogenesis in tissues using Raf and/or Ras protein, modified Raf or Ras protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Raf and/or Ras protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Raf and/or Ras protein, or nucleic acids encoding therefor. The invention also describes the use of gene delivery systems for providing nucleic acids encoding for the Raf or Ras protein, or modified forms thereof.
摘要翻译：本发明描述了使用Raf和/或Ras蛋白，修饰的Raf或Ras蛋白调节组织中血管生成的方法，以及编码这种方法的核酸。特别地，本发明描述了使用非活性Raf和/或Ras蛋白质或其编码的核酸抑制血管生成或使用活性Raf和/或Ras蛋白质或其编码的核酸来增强血管生成的方法。本发明还描述了基因递送系统用于提供编码Raf或Ras蛋白质的核酸或其修饰形式的用途。

10. 发明申请

US20060258686A1 Method of treatment of myocardial infarction 审中-公开
标题翻译：心肌梗死的治疗方法
公开(公告)号：US20060258686A1
公开(公告)日：2006-11-16
申请号：US10535325
申请日：2003-11-18
申请人： David Cheresh , Robert Paul , Brian Eliceiri
发明人： David Cheresh , Robert Paul , Brian Eliceiri
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , A01K67/0271 , A61K38/45 , A61K48/00
摘要： Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.
摘要翻译：通过向哺乳动物施用治疗有效量的化学品Src家族酪氨酸激酶蛋白抑制剂和这种抑制剂化合物用于制备用于治疗心肌梗塞的药物的用途来治疗哺乳动物的心肌梗死。可以通过向哺乳动物施用预防量的抑制剂来防止心肌梗死。抑制剂优选是Src蛋白的抑制剂，其选自吡唑并嘧啶类Src家族酪氨酸激酶抑制剂，大环二烯酮类Src家族酪氨酸激酶抑制剂，吡啶并[2,3-d]嘧啶类Src家族酪氨酸激酶抑制剂，4-苯胺基-3-喹啉甲腈类Src家族酪氨酸激酶抑制剂及其混合物。 Src家族酪氨酸激酶抑制剂可用于制备用于治疗心肌梗死的药物。还公开了含有化学Src家族酪氨酸激酶抑制剂的制品。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式